vs
Equity Residential（EQR）与欧加隆（OGN）财务数据对比。点击上方公司名可切换其他公司
欧加隆的季度营收约是Equity Residential的1.9倍（$1.5B vs $781.9M），Equity Residential净利率更高（48.9% vs -13.6%，领先62.5%），Equity Residential同比增速更快（2.0% vs -5.3%），过去两年Equity Residential的营收复合增速更高（3.4% vs -3.6%）
Equity Residential是总部位于美国的公开上市房地产投资信托基金（REIT），核心业务聚焦公寓类不动产投资，在全美多地持有大量优质公寓资产，深耕租赁住房市场，拥有成熟的运营管理经验和突出的行业竞争优势。
欧加隆是一家总部位于美国新泽西州泽西城的制药企业，核心业务覆盖生殖医学、避孕、精神科、激素替代疗法及麻醉领域的药物研发与生产。公司所有产品均在美国境外生产，同时美国市场贡献了其三分之一的营收。
EQR vs OGN — 直观对比
营收规模更大
OGN
是对方的1.9倍
$781.9M
营收增速更快
EQR
高出7.3%
-5.3%
净利率更高
EQR
高出62.5%
-13.6%
两年增速更快
EQR
近两年复合增速
-3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $781.9M | $1.5B |
| 净利润 | $382.1M | $-205.0M |
| 毛利率 | — | 49.2% |
| 营业利润率 | 50.6% | -9.8% |
| 净利率 | 48.9% | -13.6% |
| 营收同比 | 2.0% | -5.3% |
| 净利润同比 | -8.8% | -288.1% |
| 每股收益（稀释后） | $1.01 | $-0.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EQROGN
| Q4 25 | $781.9M | $1.5B | ||
| Q3 25 | $782.4M | $1.6B | ||
| Q2 25 | $768.8M | $1.6B | ||
| Q1 25 | $760.8M | $1.5B | ||
| Q4 24 | $766.8M | $1.6B | ||
| Q3 24 | $748.3M | $1.6B | ||
| Q2 24 | $734.2M | $1.6B | ||
| Q1 24 | $730.8M | $1.6B |
净利润EQROGN
| Q4 25 | $382.1M | $-205.0M | ||
| Q3 25 | $289.1M | $160.0M | ||
| Q2 25 | $192.4M | $145.0M | ||
| Q1 25 | $256.6M | $87.0M | ||
| Q4 24 | $419.1M | $109.0M | ||
| Q3 24 | $143.4M | $359.0M | ||
| Q2 24 | $177.5M | $195.0M | ||
| Q1 24 | $295.8M | $201.0M |
毛利率EQROGN
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% | ||
| Q1 24 | — | 59.0% |
营业利润率EQROGN
| Q4 25 | 50.6% | -9.8% | ||
| Q3 25 | 38.5% | 15.2% | ||
| Q2 25 | 26.6% | 14.4% | ||
| Q1 25 | 35.7% | 6.7% | ||
| Q4 24 | 57.2% | 8.1% | ||
| Q3 24 | 20.1% | 13.1% | ||
| Q2 24 | 25.3% | 14.6% | ||
| Q1 24 | 42.0% | 14.5% |
净利率EQROGN
| Q4 25 | 48.9% | -13.6% | ||
| Q3 25 | 36.9% | 10.0% | ||
| Q2 25 | 25.0% | 9.1% | ||
| Q1 25 | 33.7% | 5.8% | ||
| Q4 24 | 54.7% | 6.8% | ||
| Q3 24 | 19.2% | 22.7% | ||
| Q2 24 | 24.2% | 12.1% | ||
| Q1 24 | 40.5% | 12.4% |
每股收益（稀释后）EQROGN
| Q4 25 | $1.01 | $-0.78 | ||
| Q3 25 | $0.76 | $0.61 | ||
| Q2 25 | $0.50 | $0.56 | ||
| Q1 25 | $0.67 | $0.33 | ||
| Q4 24 | $1.10 | $0.42 | ||
| Q3 24 | $0.38 | $1.38 | ||
| Q2 24 | $0.47 | $0.75 | ||
| Q1 24 | $0.77 | $0.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $55.9M | $574.0M |
| 总债务越低越好 | $8.2B | $8.6B |
| 股东权益账面价值 | $11.0B | $752.0M |
| 总资产 | $20.7B | $12.9B |
| 负债/权益比越低杠杆越低 | 0.75× | 11.49× |
8季度趋势，按日历期对齐
现金及短期投资EQROGN
| Q4 25 | $55.9M | $574.0M | ||
| Q3 25 | $93.1M | $672.0M | ||
| Q2 25 | $31.3M | $599.0M | ||
| Q1 25 | $39.8M | $547.0M | ||
| Q4 24 | $62.3M | $675.0M | ||
| Q3 24 | $28.6M | $763.0M | ||
| Q2 24 | $38.3M | $704.0M | ||
| Q1 24 | $44.5M | $575.0M |
总债务EQROGN
| Q4 25 | $8.2B | $8.6B | ||
| Q3 25 | — | $8.8B | ||
| Q2 25 | — | $8.9B | ||
| Q1 25 | — | $9.0B | ||
| Q4 24 | $8.2B | $8.9B | ||
| Q3 24 | — | $8.7B | ||
| Q2 24 | — | $8.7B | ||
| Q1 24 | — | $8.7B |
股东权益EQROGN
| Q4 25 | $11.0B | $752.0M | ||
| Q3 25 | $11.1B | $906.0M | ||
| Q2 25 | $11.0B | $733.0M | ||
| Q1 25 | $11.0B | $542.0M | ||
| Q4 24 | $11.0B | $472.0M | ||
| Q3 24 | $10.9B | $493.0M | ||
| Q2 24 | $11.0B | $144.0M | ||
| Q1 24 | $11.1B | $48.0M |
总资产EQROGN
| Q4 25 | $20.7B | $12.9B | ||
| Q3 25 | $21.1B | $13.6B | ||
| Q2 25 | $21.0B | $13.5B | ||
| Q1 25 | $20.6B | $13.2B | ||
| Q4 24 | $20.8B | $13.1B | ||
| Q3 24 | $20.9B | $12.8B | ||
| Q2 24 | $19.8B | $12.2B | ||
| Q1 24 | $19.9B | $11.9B |
负债/权益比EQROGN
| Q4 25 | 0.75× | 11.49× | ||
| Q3 25 | — | 9.74× | ||
| Q2 25 | — | 12.14× | ||
| Q1 25 | — | 16.52× | ||
| Q4 24 | 0.74× | 18.81× | ||
| Q3 24 | — | 17.75× | ||
| Q2 24 | — | 60.11× | ||
| Q1 24 | — | 181.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $387.0M | $141.0M |
| 自由现金流经营现金流 - 资本支出 | — | $96.0M |
| 自由现金流率自由现金流/营收 | — | 6.4% |
| 资本支出强度资本支出/营收 | — | 3.0% |
| 现金转化率经营现金流/净利润 | 1.01× | — |
| 过去12个月自由现金流最近4个季度 | — | $538.0M |
8季度趋势，按日历期对齐
经营现金流EQROGN
| Q4 25 | $387.0M | $141.0M | ||
| Q3 25 | $476.7M | $264.0M | ||
| Q2 25 | $359.5M | $220.0M | ||
| Q1 25 | $425.5M | $75.0M | ||
| Q4 24 | $354.2M | $390.0M | ||
| Q3 24 | $401.4M | $141.0M | ||
| Q2 24 | $396.9M | $332.0M | ||
| Q1 24 | $421.0M | $76.0M |
自由现金流EQROGN
| Q4 25 | — | $96.0M | ||
| Q3 25 | — | $218.0M | ||
| Q2 25 | — | $181.0M | ||
| Q1 25 | — | $43.0M | ||
| Q4 24 | — | $335.0M | ||
| Q3 24 | — | $99.0M | ||
| Q2 24 | — | $300.0M | ||
| Q1 24 | — | $30.0M |
自由现金流率EQROGN
| Q4 25 | — | 6.4% | ||
| Q3 25 | — | 13.6% | ||
| Q2 25 | — | 11.4% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | 21.0% | ||
| Q3 24 | — | 6.3% | ||
| Q2 24 | — | 18.7% | ||
| Q1 24 | — | 1.8% |
资本支出强度EQROGN
| Q4 25 | — | 3.0% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 2.8% |
现金转化率EQROGN
| Q4 25 | 1.01× | — | ||
| Q3 25 | 1.65× | 1.65× | ||
| Q2 25 | 1.87× | 1.52× | ||
| Q1 25 | 1.66× | 0.86× | ||
| Q4 24 | 0.85× | 3.58× | ||
| Q3 24 | 2.80× | 0.39× | ||
| Q2 24 | 2.24× | 1.70× | ||
| Q1 24 | 1.42× | 0.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
